Observational Study
Copyright ©The Author(s) 2024.
World J Clin Cases. Jul 6, 2024; 12(19): 3845-3853
Published online Jul 6, 2024. doi: 10.12998/wjcc.v12.i19.3845
Table 1 Clinical and biochemical characteristics of all participants

HBV-related ACLF (n = 30)
CHB (n = 27)
Healthy controls (n = 20)
P value
Age (yr)42 ± 1441 ± 1539 ± 140.641
Gender (male/female)25/517/1013/70.179
Albumin (g/L)29.7 ± 4.540.1 ± 6.044.4 ± 4.3< 0.001
ALT (U/L)400.9 ± 318.8189.7 ± 121.221.1 ± 10.2< 0.001
AST (U/L)362.2 ± 249.1147.3 ± 87.020.6 ± 6.9< 0.001
TBIL (µmol/L)381.6 ± 178.141.5 ± 38.812.0 ± 3.6< 0.001
DBIL (µmol/L)216.4 ± 111.319.7 ± 23.83.7 ± 1.2< 0.001
INR2.6 ± 0.91.1 ± 0.1-< 0.001
PTA (%)35.2 ± 12.198.1 ± 16.1-< 0.001
HBVDNA (log10 copies/mL)4.7 ± 1.65.5 ± 1.6-0.084
HBeAg (+)/HBeAg (-)11/1915/12-0.153
30-d mortality19 (63.3%)0 (0)0 (0)-
Table 2 The baseline data of survivors and non-survivors with hepatitis B virus-related acute-on-chronic liver failure receiving standard medical treatment

Survivors (n = 11)
Non-survivors (n = 19)
P value
Age (yr)40 ± 1344 ± 140.467
Gender (male/female)8/317/20.327
Albumin (g/L)30.9 ± 5.229.1 ± 4.10.305
ALT (U/L)471.8 ± 319.3359.8 ± 319.90.189
AST (U/L)415.2 ± 279.7331.6 ± 232.10.451
TBIL (µmol/L)315.9 ± 182.8419.6 ± 168.40.126
DBIL (µmol/L)173.5 ± 89.6241.3 ± 117.10.109
INR2.0 ± 0.42.9 ± 0.90.001
CREA (µmol/L)84.4 ± 40.494.3 ± 62.90.747
HBVDNA (log10 copies/mL)4.8 ± 1.34.7 ± 1.80.808
HBeAg (+)/HBeAg (-)5/66/130.696
MELD score23.2 ± 6.828.8 ± 7.00.041